Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-151 + nal-IRI + 5-FU + Leucovorin in mCRC
NCT02785068Phase 2Withdrawn
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of MM-151 in metastatic colorectal cancer (mCRC), sponsored by Merrimack Pharmaceuticals. Planned start Jul 2016; status: withdrawn.
02
Drugs
MM-151
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02785068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785068.